TY - JOUR AU - Mogenet, Alice AU - Tomasini, Pascale AU - Greillier, Laurent AU - Barlesi, Fabrice PY - 2019 TI - Lorlatinib: an additional option for ALK-positive non-small cell lung cancer? JF - Translational Lung Cancer Research; Vol 8, Supplement 4 (December 31, 2019): Translational Lung Cancer Research Y2 - 2019 KW - N2 - Metastatic non-small cell lung cancer (NSCLC) remains the first cause of cancer-related death worldwide (1). Recent progress in the medical treatment of NSCLC have been focusing on molecular alterations. Anaplastic lymphoma kinase ( ALK ) rearrangements are found in about 3% to 5% of lung adenocarcinomas in western countries, more frequently non-smokers and younger patients than most NSCLC. UR - https://tlcr.amegroups.org/article/view/29328